- Home
- AGEN vs SRTS Comparison
AGEN vs SRTS Comparison
Compare AGEN & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SRTS
- Stock Information
- Founded
- AGEN 1994
- SRTS 2010
- Country
- AGEN United States
- SRTS United States
- Employees
- AGEN N/A
- SRTS N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SRTS Medical/Dental Instruments
- Sector
- AGEN Health Care
- SRTS Health Care
- Exchange
- AGEN Nasdaq
- SRTS Nasdaq
- Market Cap
- AGEN 87.7M
- SRTS 83.9M
- IPO Year
- AGEN 2000
- SRTS 2016
- Fundamental
- Price
- AGEN $4.70
- SRTS $4.71
- Analyst Decision
- AGEN Buy
- SRTS Strong Buy
- Analyst Count
- AGEN 4
- SRTS 3
- Target Price
- AGEN $13.00
- SRTS $11.67
- AVG Volume (30 Days)
- AGEN 1.7M
- SRTS 56.0K
- Earning Date
- AGEN 08-07-2025
- SRTS 08-07-2025
- Dividend Yield
- AGEN N/A
- SRTS N/A
- EPS Growth
- AGEN N/A
- SRTS N/A
- EPS
- AGEN N/A
- SRTS 0.11
- Revenue
- AGEN $99,524,000.00
- SRTS $39,488,000.00
- Revenue This Year
- AGEN $12.69
- SRTS $4.33
- Revenue Next Year
- AGEN N/A
- SRTS $31.55
- P/E Ratio
- AGEN N/A
- SRTS $43.51
- Revenue Growth
- AGEN N/A
- SRTS 24.75
- 52 Week Low
- AGEN $1.38
- SRTS $4.01
- 52 Week High
- AGEN $18.74
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- AGEN 49.92
- SRTS 47.56
- Support Level
- AGEN $4.71
- SRTS $4.50
- Resistance Level
- AGEN $5.22
- SRTS $4.99
- Average True Range (ATR)
- AGEN 0.36
- SRTS 0.20
- MACD
- AGEN -0.12
- SRTS -0.02
- Stochastic Oscillator
- AGEN 14.76
- SRTS 33.54
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.